/

Blood sugar & liver

Fatty liver disease (MASLD and MASH)

Also known as:

Metabolic dysfunction-associated steatotic liver disease, formerly NAFLD and NASH

Fat in the liver driven by metabolic risk. Common, silent and now treatable when inflammation and scarring develop.

Written and reviewed by Farhan Tahir, MD · Last reviewed

VIDEO LESSON

IN THE STUDIO
Dr. Tahir is recording this lesson.
Check back soon. New lessons are added regularly.
ANIMATED EXPLAINER · FATTY LIVER
STEP 1 OF 5
Fat overflows
Excess energy and insulin resistance push fat into the liver.

What it is

MASLD is fat in the liver plus at least one cardiometabolic risk factor such as obesity, diabetes, high blood pressure or abnormal lipids. In 2023 it replaced the term NAFLD. MASH is the inflammatory form that can scar the liver (fibrosis) and progress to cirrhosis.

How it's diagnosed

Often found on imaging or mildly abnormal liver tests. Guidelines use the FIB-4 score, from age, liver enzymes and platelets, to estimate fibrosis risk, followed by elastography (such as FibroScan) when the score is not low.

Treatment

Weight loss is the foundation: losing about 7% to 10% of body weight improves liver fat and inflammation, and larger losses can improve fibrosis. Resmetirom was FDA-approved in 2024 and semaglutide in 2025 for MASH with moderate to advanced fibrosis, without cirrhosis.

Clinical pearls

• Cardiovascular disease is the leading cause of death in MASLD.

• Limit alcohol: it adds liver injury.

Educational content only, written and reviewed by Farhan Tahir, MD. It does not replace individual medical advice. For sudden chest pain, trouble breathing or stroke symptoms, call 911.

AT A GLANCE

Category

Blood sugar & liver

Also known as

Metabolic dysfunction-associated steatotic liver disease, formerly NAFLD and NASH

Reviewed by

Farhan Tahir, MD

Questions about your own care?

Dr. Tahir’s team offers consults through Youthful Medicine.